on Biophytis (EPA:ALBPS)
Biophytis Unveils Obesity and Sarcopenia Programs at ICFSR Conference
Biophytis, a biotechnology firm at the forefront of developing treatments aimed at longevity, recently showcased its advancements at the ICFSR Conference in Washington, DC. The event, dedicated to frailty, sarcopenia, and aging mechanisms, gathered researchers and industry experts to foster clinical trials in these areas.
During the conference, Dr. Cendrine Tourette, Biophytis' Director of Clinical Programs, presented on BIO101, focusing on its potential for obesity treatments. This presentation highlighted the upcoming Phase 2 program for BIO101. Additionally, Biophytis engaged in the Biotech Showcase to communicate the latest progress in their SARA program targeting sarcopenia.
Biophytis' involvement at ICFSR reflects its dedication to advancing scientific research in age-related conditions and forging innovative therapies to support healthy aging.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news